2019年 · 第42卷第05期

This issue is the key number of tuberculosis, which reflects the current diagnosis and treatment of tuberculosis from multiple angles. In the review column, Li Liang et al. said in the article "It is urgent to strengthen the research on anti-tuberculosis drug-induced liver injury in China" that "anti-tuberculosis drug-induced liver injury (ATB-DILI) is a common toxicity and adverse reaction of anti-tuberculosis drugs, and the consequences are serious if the diagnosis and treatment are delayed. How to reduce or avoid ATB-DILI has always troubled the majority of tuberculosis prevention and treatment workers. The mechanism of ATB-DILI is complex, we still know little about it, and the clinical manifestations are often atypical. The mechanism and efficacy of hepatoprotective therapy are still uncertain, and the role of preventive hepatoprotective therapy is not yet clear. Many new ideas and new understandings need further clinical verification, and systematic clinical and basic research is needed."

Chronic obstructive pulmonary disease (COPD) is a chronic progressive lung disease with persistent respiratory symptoms and restricted airflow. Its prevalence is gradually increasing. At present, it is estimated that there are nearly 100 million COPD patients in China^[1]。 Choosing appropriate therapeutic drugs for COPD is an important part of COPD management. In recent years, COPD core therapy has begun to revolve around double bronchodilators [long-acting muscarinic antagonist (LAMA) /long-acting beta₂The role of long-acting beta2-agonist (LABA)] in the treatment of COPD and the efficacy of the triple formulation LAMA/LABA/inhaled corticosteroid (ICS) are discussed. This article will introduce the latest research progress of bibronchodilators and triple formulations.